New CEO Emma Walmsley shows she is not afraid to ruffle feathers at GSK

7 August 2017

It seemed inevitable that change was on the horizon when Emma Walmsley’s appointment as chief executive of UK pharma major GlaxoSmithKline (LSE: GSK), taking over from Sir Andrew Witty, was announced nearly a year ago.

Ms Walmsley’s background, coming from cosmetics giant L’Oréal and more recently GSK’s consumer division rather than its core pharmaceuticals business, marked her out as different, as did the fact that she was the first woman chief executive of a big drugmaker in the UK.

The Financial Times has noted, in an interview with Ms Walmsley and an update on her progress, that this change has started to arrive.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK